The European Medicine Agency Validates the Gilead Application for a CAR T Product for Mantle Cell Lymphoma

The EMA validated the MAA for the Gilead Investigational CAR T Product for MCL
Kite, a Gilead (GILD) company, announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) of the investigational CAR T product KTE-X19 for adult patients with relapsed or refractory mantle cell lymphoma (MCL

This content is for paid subscribers.
Please click here to subscribe or here to log in.